Clinical Trial Update: An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacitidine plus durvalumab in untreated higher-risk myelodysplastic syndromes or elderly AML patients, with completed status and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Durvalumab (durvalumab)

Snippet

Sponsor: Celgene | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2020-05-04